Bethel MA - Search Results

1

Efficacy and safety of dulaglutide 3.0 and 4.5 mg in patients aged younger than 65 and 65 years or older: Post hoc analysis of the AWARD-11 trial.

Frias JP, Bonora E, Nevárez Ruiz L, Hsia SH, Jung H, Raha S, Cox DA, Bethel MA, Konig M. Frias JP, et al. Among authors: bethel ma. Diabetes Obes Metab. 2021 Oct;23(10):2279-2288. doi: 10.1111/dom.14469. Epub 2021 Jul 8. Diabetes Obes Metab. 2021. PMID: 34159708 Free PMC article. Clinical Trial.

2

Efficacy and Safety of Dulaglutide 3.0 mg and 4.5 mg Versus Dulaglutide 1.5 mg in Metformin-Treated Patients With Type 2 Diabetes in a Randomized Controlled Trial (AWARD-11).

Frias JP, Bonora E, Nevarez Ruiz L, Li YG, Yu Z, Milicevic Z, Malik R, Bethel MA, Cox DA. Frias JP, et al. Among authors: bethel ma. Diabetes Care. 2021 Mar;44(3):765-773. doi: 10.2337/dc20-1473. Epub 2021 Jan 4. Diabetes Care. 2021. PMID: 33397768 Free PMC article. Clinical Trial.

3

HbA_1c Change and Diabetic Retinopathy During GLP-1 Receptor Agonist Cardiovascular Outcome Trials: A Meta-analysis and Meta-regression.

Bethel MA, Diaz R, Castellana N, Bhattacharya I, Gerstein HC, Lakshmanan MC. Bethel MA, et al. Diabetes Care. 2021 Jan;44(1):290-296. doi: 10.2337/dc20-1815. Diabetes Care. 2021. PMID: 33444163 Free PMC article. Review.

4

Glycaemic efficacy of an expanded dose range of dulaglutide according to baseline glycated haemoglobin (HbA1c) subgroup: Post hoc analysis of AWARD-11.

Frias JP, Bonora E, Cox DA, Bethel MA, Kwan AYM, Raha S, Malik RE. Frias JP, et al. Among authors: bethel ma. Diabetes Obes Metab. 2021 Dec;23(12):2819-2824. doi: 10.1111/dom.14533. Epub 2021 Sep 14. Diabetes Obes Metab. 2021. PMID: 34463420 Free PMC article. Clinical Trial.

5

Gastrointestinal Tolerability of Once-Weekly Dulaglutide 3.0 mg and 4.5 mg: A Post Hoc Analysis of the Incidence and Prevalence of Nausea, Vomiting, and Diarrhea in AWARD-11.

Van J, Frias JP, Bonora E, Raha S, Meyer J, Jung H, Cox D, Konig M, Peleshok J, Bethel MA. Van J, et al. Among authors: bethel ma. Diabetes Ther. 2021 Oct;12(10):2783-2794. doi: 10.1007/s13300-021-01140-9. Epub 2021 Sep 12. Diabetes Ther. 2021. PMID: 34514554 Free PMC article.

6

Effect of expanded dulaglutide weekly doses (3.0 mg and 4.5 mg) on cardiovascular disease risk factors in participants with type 2 diabetes at increased cardiovascular disease risk: a post hoc analysis of the AWARD-11 study.

Cox DA, Wang H, Nicolay C, Bethel MA. Cox DA, et al. Among authors: bethel ma. Diabetes Obes Metab. 2022 Sep;24(9):1770-1778. doi: 10.1111/dom.14762. Epub 2022 May 29. Diabetes Obes Metab. 2022. PMID: 35546790 Free PMC article.

7

Gender differences in cardiovascular risk, treatment, and outcomes: a post hoc analysis from the REWIND trial.

Ferrannini G, Maldonado JM, Raha S, Rao-Melacini P, Khatun R, Atisso C, Shurzinske L, Gerstein HC, Rydén L, Bethel MA. Ferrannini G, et al. Among authors: bethel ma. Scand Cardiovasc J. 2023 Dec;57(1):2166101. doi: 10.1080/14017431.2023.2166101. Scand Cardiovasc J. 2023. PMID: 36723445 Free article. Clinical Trial.

8

Biomarker Changes Associated With Both Dulaglutide and Cardiovascular Events in the REWIND Randomized Controlled Trial: A Nested Case-Control Post Hoc Analysis.

Gerstein HC, Lee SF, Paré G, Bethel MA, Colhoun HM, Hoover A, Lakshmanan M, Lin Y, Pirro V, Qian HR, Ruotolo G, Ryden L, Wilson JM, Duffin KL. Gerstein HC, et al. Among authors: bethel ma. Diabetes Care. 2023 May 1;46(5):1046-1051. doi: 10.2337/dc22-2397. Diabetes Care. 2023. PMID: 36897834 Clinical Trial.

9

Regional, age and sex differences in baseline characteristics of patients enrolled in the Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS).

Bethel MA, Green JB, Milton J, Tajar A, Engel SS, Califf RM, Holman RR; TECOS Executive Committee. Bethel MA, et al. Diabetes Obes Metab. 2015 Apr;17(4):395-402. doi: 10.1111/dom.12441. Epub 2015 Feb 13. Diabetes Obes Metab. 2015. PMID: 25600421 Clinical Trial.

10

Sitagliptin and risk of fractures in type 2 diabetes: Results from the TECOS trial.

Josse RG, Majumdar SR, Zheng Y, Adler A, Bethel MA, Buse JB, Green JB, Kaufman KD, Rodbard HW, Tankova T, Westerhout CM, Peterson ED, Holman RR, Armstrong PW; TECOS Study Group. Josse RG, et al. Among authors: bethel ma. Diabetes Obes Metab. 2017 Jan;19(1):78-86. doi: 10.1111/dom.12786. Epub 2016 Oct 6. Diabetes Obes Metab. 2017. PMID: 27607571 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

86 results

Search Page

Filters